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Abstract
Background: Neonatal trials remain difficult to conduct for several reasons: in particular the need for study sites to have an
existing infrastructure in place, with trained investigators and validated quality procedures to ensure good clinical,
laboratory practices and a respect for high ethical standards. The objective of this work was to identify the major criteria
considered necessary for selecting neonatal intensive care units that are able to perform drug evaluations competently.
Methodology and Main Findings: This Delphi process was conducted with an international multidisciplinary panel of 25
experts from 13 countries, selected to be part of two committees (a scientific committee and an expert committee), in order
to validate criteria required to perform drug evaluation in neonates. Eighty six items were initially selected and classified
under 7 headings: ‘‘NICUs description - Level of care’’ (21), ‘‘Ability to perform drug trials: NICU organization and processes
(15), ‘‘Research Experience’’ (12), ‘‘Scientific competencies and area of expertise’’ (8), ‘‘Quality Management’’ (16), ‘‘Training
and educational capacity’’ (8) and ‘‘Public involvement’’ (6). Sixty-one items were retained and headings were rearranged
after the first round, 34 were selected after the second round. A third round was required to validate 13 additional items.
The final set includes 47 items divided under 5 headings.
Conclusion: A set of 47 relevant criteria will help to NICUs that want to implement, conduct or participate in drug trials
within a neonatal network identify important issues to be aware of.
Summary Points: 1) Neonatal trials remain difficult to conduct for several reasons: in particular the need for study sites to
have an existing infrastructure in place, with trained investigators and validated quality procedures to ensure good clinical,
laboratory practices and a respect for high ethical standards. 2) The present Delphi study was conducted with an
international multidisciplinary panel of 25 experts from 13 countries and aims to identify the major criteria considered
necessary for selecting neonatal intensive care units (NICUs) that are able to perform drug evaluations competently. 3) Of
the 86 items initially selected and classified under 7 headings - ‘‘NICUs description - Level of care’’ (21), ‘‘Ability to perform
drug trials: NICU organization and processes (15), ‘‘Research Experience’’ (12), ‘‘Scientific competencies and area of
expertise’’ (8), ‘‘Quality Management’’ (16), ‘‘Training and educational capacity’’ (8) and ‘‘Public involvement’’ (6) - 47 items
were selected following a three rounds Delphi process. 4) The present consensus will help NICUs to implement, conduct or
participate in drug trials within a neonatal network.
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Introduction
In the neonatal population, more than 90% of products are
used unauthorised or off-label, especially when neonates are
treated in Neonatal Intensive Care Units (NICUs). New
treatments are often introduced in the neonatal therapeutic arena
without specific evaluation, on the basis that they have proven
efficacy in adults and older children. Altogether, many drugs, even
when authorised for use in neonates, would benefit from further
validated data and a consensus among neonatologists to ensure the
most optimal use. In order to improve this situation, a few
initiatives were undertaken starting in the USA with the Food and
Drug Administration Modernization Act and Best Pharmaceuti-
cals for Children Act respectively in 1997 and 2002, and the
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American Paediatric Research Equity Act and Newborn Drug
Initiative respectively in 2003 and 2006. Similarly in Europe, the
European Paediatric Regulation entered in force in June 2007 to
increase the development of medicines for all paediatric age
groups, including neonates.
There are many major and already well-known practical and
ethical issues in conducting drug evaluation in neonates [1,2].
Although neonates represent only a small part of the population,
they have specific diseases and high variations in disease
presentations with a major risk of unfavorable long-term outcome.
Evaluation of drug pharmacokinetics, efficacy and safety are
required in the different neonatal age groups from 24 to 44 weeks’
gestational age, characterised by differences in physiological and
pharmacological maturation affecting drug disposition and effects
[3,4]. Suitable approaches, adapted to neonates are recommended
but need to be more widely used: population pharmacokinetic and
bridging studies [5,6], adapted designs and other methodologies
recognised as pertinent to evaluate efficacy when randomized
controlled trials are not possible [7–9].
Many of these issues can be solved by bringing together
scattered expertise within a neonatal network dedicated to drug
evaluation in neonates, in collaboration with the European Society
of Developmental, Perinatal and Paediatric Pharmacology
(ESDPPP). According to the request of the European Commission
and following the EnprEMA network initiative (European
Network of Paediatric Research at the European Medicines
Agency), we conducted a Delphi process [10–14] to identify the
criteria that would help neonatologists to organise a NICU
research infrastructure in order to conduct drug evaluation trials
and be part of a European network for drug evaluation in
neonates.
Methods
Ethics Statement
The study did not need institutional review board approval as it
did not affect patient care, and the information that it generated
was used for consensual quality criteria only.
The objectives of the Delphi study were presented to all
participants, their agreement and availability to participate were
obtained (their written consent consisted of replying positively by
email to the invitation sent by the organisers), and their
independency verified.
Organization of the Delphi Study
The objective of the Delphi study was to obtain a consensus on
the prerequisites that NICUs need to fulfil in order to perform
clinical drug trials. Two experts groups conducted the Delphi
study by email between February 2012 and February 2013.
Composition of the Scientific and Expert Committees
Two expert groups conducted the Delphi study: the Scientific
Committee consisted of 10 experts responsible for organising the
Delphi device, selecting and/or approving the members of the
Expert Committee, drafting the successive versions of the
questionnaire, and analysing the data after each round (questions
and answers, results). All members of the Expert Committee (the
panellists) agreed to answer the questionnaire during each round
and to criticize the answers if necessary.
All the participants (Table 1) were initially selected by the
organisers (FL & EJA) in order to ensure that they will represent all
potential differences in background, occupational environment,
clinical approaches or practices. They were contacted because of
their recognised expertise in the different areas of knowledge
required for drug evaluation in neonates (neonatology, pharma-
cology, clinical research), after evaluation of teaching functions,
publications, participations to international scientific societies,
scientific and ethic boards or networks). The composition of the
Scientific and Expert committees included clinical investigators
(paediatricians or neonatologists), pharmacologists or pharmacists,
researchers, regulators, and employed by industry, academia or
regulatory agencies and in most cases members of scientific
societies and clinical networks. They were from various countries/
continents, had a broad range of ages and different levels of
expertise. All the members of the Scientific committee agreed on
the composition of the groups, and accepted to participate. The
expert selection was then submitted for approval to the Scientific
Committee, and finally two additional members were added upon
their suggestions.
Questionnaire preparation
The Scientific Committee drafted the first version of the
questionnaire, composed of questions and simple items. Each
member proposed recognition criteria and a total of 105 items
were listed. They were then invited to confirm and/or refine all
the items to allow them to be rated during the Delphi process. The
resulting questionnaire was submitted a third time by the
organisers, for validation by each member of the Scientific
Committee. Finally, the elaborated questionnaire included 86
items divided over 7 headings: (Table 2, column A): H1:
‘‘NICUs description - Level of care’’ (21 items), H2: ‘‘Ability to
perform drug trials: NICU organization and processes’’ (15 items),
H3: ‘‘Research experience of the NICU’’ (12 items), H4:
‘‘Scientific competencies and capacity to provide expert advice’’
(8 items), H5: ‘‘Quality management’’ (16 items), H6: ‘‘Training
and educational capacity’’ (8 items), and H7: ‘‘Public involve-
ment’’ (6 items).
Rounds
As required in a Delphi study, each item is required to be
assessed twice, using a 1st and a 2nd level of consensus to be finally
selected.
First round
The first round was performed from February to July 2012. The
panellists (Expert Committee) received the first questionnaire by
electronic mail and they were invited to rate their agreement about
each item on a 9-point scale, where 1 meant definitely not agree
and 9 definitely agree. They were also invited to comment on each
item using a dedicated ‘‘comment box’’, and/or to add items
considered as important. Items were included in the second round
if a consensus was reached based on two selection criteria: a
median score in the top tertile (7–9) and at least 65% of panel
ratings in the top tertile (1st level of consensus). At the end of the
first round, the questionnaire was slightly modified by the scientific
committee and a few items were added to take into account
comments and suggestions of the panellists.
Second round/Third round
The second round was conducted between November and
December 2012. All panellists who had participated in the first
round were sent the second-round questionnaire by email, with
the results of the first round including median panel rating,
frequency distribution rating as well as their individual ratings
from the first round. They were asked to re-score each item based
on their own opinion, and the panel responses obtained during the
first round. The second round also included a limited number of
Delphi Process to Perform Drugs Trials in NICUs
PLOS ONE | www.plosone.org 2 September 2014 | Volume 9 | Issue 9 | e104976
‘‘new’’ items, not evaluated in the first round and that had to send
out from a second evaluation during what has been called a ‘‘third
round’’ in order to evaluate each item twice. This third round took
place between January and February 2013. To be included in the
final list, the items were selected by the level of median rating in
the top tertile (7–9) and a 75% agreement among panellists that
the rating was in the top tertile (7–9) (2nd level of consensus).
Results
The characteristics of the two experts groups (n = 25) are
presented Table 1 and they are all listed in alphabetic order in
the ‘‘Acknowledgment’’ section. They were selected because they
had at least 10 years’ experience and a well-known international
recognition in their field of expertise.
The members of the Scientific Committee were selected and
contacted by the organisers, and all of them agreed (10/10, 100%)
to participate.
Of the twenty panellists appointed by the Scientific Committee
to participate to the Delphi rounds, 15 (79%) accepted: 9 were
neonatologists, 2 were pharmacologists, 2 were institutional and
industrial project managers and 1 was a neonatologist/scientific
officer in a regulatory authority. All of them participated in the
three rounds of the process.
First round
The 7 headings comprising a total of 86 initial items tested
during the first round are listed in Table 2, column A
(Figure 1).
Fifty-seven items reached the first level of consensus (57/86,
66%) (Table 2, column A), while twenty-nine items were
discarded (29/86, 34%): 16 (19%) because of a median rating
lower than 7, and 13 (15%) because less than 65% of panellists
gave rating in the top tertile [7–9].
Adjustments at the end of the first round. Adjustments
were made prior to the second round, taking into account the
suggestions and comments of the Expert Committee and the
Scientific Committee review (Table 2, column B): rearrange-
ments of headings and redefinition of a few items were made, such
as H3: ‘‘Research Experience’’ and H6: ‘‘Training and educa-
tional capacity’’ that were re-organized and included under the
first heading H1: ‘‘NICUs Description’’; a few items were better
defined (H1: i6; and i40; H2: i33 to i35; H3: I49; H4: I65, i66 and
i72), while others were compiled into new items (H1: i69and i759;
H2: i269; H4: i609; and H5: i829); and a new ‘‘Access to electronic
record’’ was added (H2: i369).
After these adjustments, the questionnaire included 61 items
under 5 headings (Table 2, column B) as: from 57 items selected
in this first round, 53 items remained; similarly, among the 29
discarded items in the previous round, 7 items were maintained to
be re-assessed in the second round; and one additional item was
added.
Second round
At this step of the process, 61 items were therefore evaluated,
including modified, retained or additional items (27 items), which
were considered as ‘‘new items’’ and were rated for the first time
through this second round. Results are presented Table 2.
47 items were selected (47/61, 77%). Among them, 34 items
were definitively retained based on the second level of consensus,
and 13 items required to be re-assessed (second assessment)
through a third round (Figure 1). The remaining 14 items were,
for their part, definitively discarded.
Third round
The previous 13 items that were re-assessed reached the second
level of consensus and were definitively selected.
Final results
At the end of the process, 47 items were finally selected
according to the second level of consensus and divided under 5
headings (Table 3 and Figure 1).
Table 1. Main characteristics of the Expert and Scientific Committees.
CHARACTERISTICS Scientific Committee (n =10) Expert Committee (n =15
Sex, n (%)
Female 2 (20) 3 (20)
Male 8 (80) 12 (80)
Age (years), median (q1, q3) 51 (44, 58) 52 (49, 57)
Years of experience, median (q1, q3) 22 (19, 29) 24 (21, 30)
Present professional setting, n (%)
Industrial/Private 0 (0) 2 (13)
Institutional 10 (100) 13 (87)
Speciality, n (%)
Regulation and Trial management 1 (10) 4 (27)
Pediatric pharmacology 3 (30) 2 (13)
Neonatology 6 (60) 9 (60)
Geographical origin, n (%)
Europe 6.5 (65) 11 (73)
Asia 0 (0) 2 (13)
US/Canada 2.5 (25) 1 (7)
Australia 1 (10) 1 (7)
doi:10.1371/journal.pone.0104976.t001
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Discussion
Drug trials should always be conducted in sites that can
guaranty quality, performance and high ethical standards and this
is obviously of even greater importance in neonatal drug
evaluations. In this context, the present Delphi study was
conducted to define criteria that neonatologists should consider
to optimise organisation of the NICU, trial management and
conduct. Starting from 86 items divided in 7 headings, a consensus
among 15 multidisciplinary experts with a wide range of
experience in neonatology, experimental or regulatory practices
identified 47 items in 5 re-organised headings (Figure 1). These
criteria should help to set up a network of NICUs specialised in
drug evaluation in neonates.
As previously stated, drug research in neonates is difficult and,
consequently, the number of neonatal drug trials is limited and
sometimes of poor quality [7]. Therefore, collaborative, multicen-
ter and multinational studies are essential to recruit neonates with
similar diseases from various regions or countries in order to
obtain a sample size of sufficient magnitude and to conduct
scientific sound studies. In addition to increasing recruitment
capacities, such specialised centers will ‘‘combine and share’’
competences in order to build a network to guaranty trial quality
and performances, but also to develop investigator and nurse
training. This approach is in agreement with the request of the
European Commission and is currently supported by the
European Medical Agency that developed the EnprEMA network,
‘‘a network of networks’’ [15].
Most of the paediatric networks that we are aware of are so
called ‘‘Paediatric improvement networks’’, collaborating to
reduce the gaps and disparities in health care quality and improve
outcomes by accelerating the translation of evidence into practice
[16–18]. They are mostly organised in paediatric subspecialties
such as the Children’s Oncology Group (COG) in the USA, the
Paediatric Rheumatology INternational Trials Organization
(Pinto) and the Paediatric European Network for Treatment of
AIDS (Penta) in Europe [15]. Some of them are dedicated to
perinatal or neonatal care such as the California Perinatal Quality
Care Collaborative (CPQCC) [16,19] but many other national or
Figure 1. Flowchart of the Delphi process.
doi:10.1371/journal.pone.0104976.g001
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regional initiatives do exist [17]. All of them underline the
importance of a close link with research although limited networks
of NICUs were set up for research purposes. In the USA, the
Paediatric Pharmacology Research Units network (PPRU) was a
cooperation of clinical centers participating in the cooperative
agreement with NICHD and represented academic institutions
with experience in multi-center clinical research. They agreed to
abide by the study protocols and have comparable staff, facilities,
and equipment.
In Europe, the European Neonatal Network (EuroNeoNet)
primarily aims to give European neonatologists a tool to perform
their own quality assurance and benchmarking. Additional
neonatal networks do exist at the national level in most countries,
including the German Neonatal Network (GNN), the National
Institute for Health Research Medecines for clinical research
network (NIHR) in the UK, and the Paediatric Clinical
Investigation Centers in France (CIC). However, the criteria that
might facilitate initial adhesion and follow-up of the NICUs that
are members of a neonatal network are not easily identified. The
present Delphi study was conducted in order to combine opinions
into group consensus on this topic and is reported here according
to published recommendations [20].
The first heading ‘‘NICUs description’’ includes subdivisions
focussing on ‘‘Level of care, Research experience and Training -
Education capacities’’ with description of the size, organization,
and teaching hospital status. All the items related to ‘‘highly
specialised care technics’’ (such ECMO, or cooling) were put
together as the centers providing them are highly specialised and
always identified at the regional or national level. Therefore, the
corresponding NICUs will be identified within a network and
contacted at the initial step of study feasibility if such technics are
required by the protocol.
The term ‘‘feasibility’’ is currently used but may cover different
issues: for industry, the question behind feasibility is: do the
patients corresponding to the inclusion criteria really exist and in
addition, where do we find them? Indeed, when industry-driven,
the protocol is developed according to regulatory guidelines for
drug evaluation in neonates [3] and follows a Paediatric
Investigation Plan that is binding. There are concerns that these
may not always feasible in the neonatal population however, as per
current experience with TINN (Treat Infections iN Neonates)
projects (TINN1 and TINN2) - very few indications of the drug
limiting inclusions for a RCT; registry considered as non-
informative. In contrast, for clinicians, feasibility primarily means:
is this acceptable for the patient and his parents? Do we have time
and staff for this? Indeed, analysis of feasibility by a local Scientific
Review Board with the medical and nurse staff is essential to
evaluate recruitment capacities within predefined calendars and in
our experience, the best response may sometimes be NO [21,22].
Research activities will be reported annually in centers already
conducting drug trials, underlining the major importance to be
given to performances evaluated in terms of adherence, number of
patients included, queries. Continuous re-evaluations of quality
and performances are now currently performed in neonatal
intensive care and with significant results in terms of long-term
quality-adjusted survival [23]. They are also required to evaluate
research activities, ensure that all organisational and training
efforts are maintained, allowing to reach positive results in terms of
recruitment, adherence to timelines, quality and Ethics. Although
discussed, additional criteria such as success in grant applications
and/or publications were thought to reflect more networking
activities than individual NICU activities and performances.
Three headings ‘‘NICUs organisation, Scientific competencies,
Quality management’’ include all the items required to guaranty
quality and performances of clinical research. Among key items, a
Table 4. Standard Operating Procedures (SOPs).
1. Writing, Reviewing & Communication procedures: Format and
style, Document control and version numbering, New SOPs, Review of SOPs,
Withdrawal, Training, Communication, Organizing protocol information, etc…
2. Principles and Procedure of Informed Consent: Screening, Informing of
participants, Obtaining proxy informed consent, Ongoing consent procedure
3. Amendments to the Protocol and Protocol-Related Documentation:
Identification of need of amendment, Substantial amendments, Non-substantial
amendments, Implementation of amendments, Urgent Safety measures
4. Quality Control and Quality Assurance Procedures: Standard operating
procedures, Trial master file, Protocol, Oversight Committees, Data management
and monitoring, Audit and inspection
5. Trial Pharmacy Procedures - Management of IMP supplies: Supply
and importing of Study Products (IMP and/or Placebo), Packaging and labelling,
QP release, Supply chain, Pharmacy procedures, Investigational Drug
Accountability Record, Prescription Numbering, Storage requirements,
Re-labelling, Product recall
6. Training and initiation of study centres: Trial set-up, Delegation of duties
and signature log, Site initiation, Site activation, Ongoing training and monitoring
7. Preparation and validations of the eCRF
8. Management of Essential Documentation: Trial Master File (TMF),
Investigator Site File (ISF), Investigators Brochure, Monitoring plan, Data
Management Plan, Statistical Analysis Plan, ISMB charter, Archiving of
Essential Documentation, Document storage and access, ISMB charter
9. Statistical Procedures
10. Pharmacovigilance Procedures: Reference safety information, Events to be
recorded, Pharmacovigilance training, Reporting responsibilities - Principal
Investigators, Reporting responsibilities - Sponsor, Development Update Safety
Report, Other safety issues
11. Study closure procedures: Activities prior to closure, Routine site
closure, Early closure
12. Document Control Procedures: Generation of new documentation, Version
control, Document storage and access, Translation of non-critical controlled
documentation, Document revision
13. Managements of protocol deviations and serious breach, Deviations
pre-identified in monitoring plan, Ad hoc incident reports, etc…
14. Study reports: Development update safety report, Annual report to ethics
committee, Declaration of end of the trial, End of study report
15. Laboratory procedures: Pharmacokinetic samples, Receipt, handling
and storage of Microbiology samples, Analysis of Microbiology samples
16. Trial Auditing and Inspection: Procedure in case of research fraud and
misconduct of the trial, etc…
doi:10.1371/journal.pone.0104976.t004
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clear identification of the research staff, including senior doctors
and nurses are key factors to insure quality. The role of nurses in
improving neonatal care and outcome has been demonstrated
[24]. Similarly, their role in clinical research should be better
acknowledged and recognised. As neonates hospitalised in
intensive care are the most nurse-intensive patients, conducting
clinical drug research requires additional dedicated research
nurses. In such context, the required neonate - research/nurse
ratio in a given NICU obviously depends upon research workload
related to the trials and should also include time for training care
nurses, availability for parents’ information and all additional tasks
related to quality and ethics [25].
Although research in neonates is almost always preceded by
research in adults and children, diseases in neonates are different
in terms of clinical presentation, evolution and risks. It is therefore
essential for researchers and pharmaceutical industry people to get
advice from experts in the NICU and its surrounding [26], as
involvement in pharmacokinetic and pharmacodynamics drug
evaluation, trial designs adapted to low numbers, is expected. The
quality management is based on Standard Operating Procedures,
i.e documents with detailed instructions, written to describe steps
to follow in all activities under defined conditions. They are
derived from knowledge of Good Clinical and Laboratory
Practices from International Conference on Harmonisation (ICH
guideline Q11); and Good Laboratory Practice (GLP) from the
Organisation for Economic Cooperation and Development
(OECD). Such knowledge is required for all health professionals
participating in a clinical trial. In particular, the roles, obligations
and responsibilities of the sponsor and all health professionals,
respect of ethical standards focussing on parental information and
consent are clearly defined. The major ‘‘Quality SOPs’’ available
in any research center and that have been used and adapted to the
TINN2 multicenter European drug trial in neonates are listed
Table 4.
Among them, ‘‘Trial Pharmacy Procedures’’ including proce-
dures related to ‘‘preparation and administration of the IMPs’’ are
essential as dilutions, sometimes multiple, of a concentrated
product, low volumes of infusion, potential physico-chemical
interactions are key issues [27,28]. In addition, in this heading,
adherence to trial dependent - standard operating procedures
should be evaluated by monitors on a regular basis, and
documentation and report of all adverse drug reactions.
The last heading is related to ‘‘Public involvement’’. The
philosophy of ‘‘Family-centered care’’ referring to a partnership
between parents and the medical staff [29] focuses on involving
them in all ethical and medical decisions related to their newborn’s
care [30]. Similarly, decisions regarding neonatal research
enrollment need to be made conjointly with parents and health
care professionals and many studies are now available to improve
the consent process [31–33]. Researchers are also concerned by
involving parents in an earlier phase, in order to help drafting the
information and consent documents and make them more
accessible to parents, as reflected in the selected items kept in
the heading. One item ‘‘Involvement of parents and their
representatives or organisations in trial design’’ was not selected,
probably because ‘‘Trial design’’ refers to specific methodologies
to optimize drug trials taking into account neonatal specificities. In
contrast, trials dealing with safety evaluation or long-term follow
up are to be discussed extensively with parents in order to evaluate
their view on how the child and the whole family will be involve,
on how to face open questions on outcome and potential sequelae
or neurodevelopmental disorders.
In conclusion, this is to our knowledge, the first consensus
obtained by experts and aiming to list the items that should be
considered to organize a neonatal network of specialised intensive
care units dedicated to drug evaluation. Some of these items may
not be required in all units but should be identified to optimize
trial design, conduct highly specialised evaluations and train health
professionals to trial conduct for the benefit of neonates and their
parents.
Acknowledgments
This work is part of the GRIP project (Global Research in Paediatrics)
which aims to implement an infrastructure matrix to stimulate and
facilitate the development and safe use of medicine in children. GRiP
objectives are to create consensus on international standards, methodol-
ogies and tools for paediatric research.
This study is dedicated to Adolfo Valls-i-Soler who sadly passed away
prematurely on December 2013.
We are grateful for the contribution of the expert and scientific panel
members.
Expert Committee
Amparo Alemany (TFS - Trial Form Support, Madrid, Spain), Yannick
Aujard (Hoˆpital Robert Debre´, Paris, France), Ralph Bax (EMA, London,
UK), Andrew Davidson (Royal Children’s Hospital, Victoria, Australia),
Laura Fabbri (Chiesi Farmaceutici, Parma, Italy), Henry Halliday (Queen’s
University, Belfast, Northern Ireland), Egbert Herting (Klinik fu¨r Kinder
und Jugendmedizin, Lu¨beck, Germany), Shinya Hirano (Osaka Medical
Center and Research Institute for Maternal and child Health, Osaka,
Japan), Christine Kubiak (ECRIN, Paris, France), Florian Lagler (Salzburg
University Childrens Hospital, Salzburg, Austria), Jean-Paul Langhendries
(CHC - NICU Site St Vincent, Liege-Rocourt, Belgium), Emmanuel
Lopez (NICU Port Royal, Cochin Hospital, Paris, France), Michael Rieder
(University of Western Ontario, London, Canada), Bo Sun (Children’s
Hospital of Fudan University, Shanghai, China), Anton van Kaam (Emma
Children’s Hospital, Academic Medical Center, Amsterdam, Netherlands).
Scientific Committee
Noel Cranswick (Royal Children’s Hospital, Melbourne, Australia), Elin
Haf Davies (EMA, London, UK), Wolfgang Go¨pel (Klinik fu¨r Kinder- und
Jugendmedizin, Lu¨beck, Germany), Carlo Giaquinto & Ursula Trafojer
(Paediatric European Network Treatment AIDS (PENTA), Padova, Italy),
Evelyne Jacqz-Aigrain (Hoˆpital Robert Debre´, INSERM, Paris, France),
Gregory Kearns (Children’s Mercy, Kansas city, Missouri (USA), Thierry
Lacaze-Masmonteil (Children Hospital of Eastern Ontario, Ottawa,
Canada), Mark Turner (Liverpool Women’s NHS Foundation Trust,
Liverpool, UK), Adolf Valls-i-Soler & Elizabeth Valls (Cruces University
Hospital, Bilbao, Spain), John Van Den Anker (Children’s National
Medical Center, Washington, USA & Sophia Children’s Hospital,
Rotterdam, Netherlands).
Author Contributions
Conceived and designed the experiments: FL EV AVS JVA EJA.
Performed the experiments: FL RB SL VE EJA. Analyzed the data: FL
EV JVA AVS EJA. Contributed reagents/materials/analysis tools: FL RB
EJA. Wrote the paper: FL EJA.
References
1. Jacqz-Aigrain E, Kaguelidou F, van den Anker JN (2012) How to optimize the
evaluation and use of antibiotics in neonates. Pediatr Clin North Am 59: 1117–
1128. doi:10.1016/j.pcl.2012.07.004.
2. Ellsbury DL, Ursprung R (2012) A quality improvement approach to optimizing
medication use in the neonatal intensive care unit. Clin Perinatol 39: 1–10.
doi:10.1016/j.clp.2011.12.001.
3. CHMP & PDCO - ‘‘Guideline on the investigation of medicinal products in the
term and preterm neonate’’ (2009) Guideline on the investigation of medicinal
products in the term and preterm neonate. Available: http://www.ema.europa.
eu/docs/en_GB/document_library/Scientif ic_guideline/2009/09/
WC500003750.pdf.
4. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, et al.
(2003) Developmental pharmacology–drug disposition, action, and therapy in
Delphi Process to Perform Drugs Trials in NICUs
PLOS ONE | www.plosone.org 14 September 2014 | Volume 9 | Issue 9 | e104976
infants and children. N Engl J Med 349: 1157–1167. doi:10.1056/
NEJMra035092.
5. Tod M, Jullien V, Pons G (2008) Facilitation of drug evaluation in children by
population methods and modelling. Clin Pharmacokinet 47: 231–243.
doi:10.2165/00003088-200847040-00002.
6. Cella M, Zhao W, Jacqz-Aigrain E, Burger D, Danhof M, et al. (2011) Paediatric
drug development: are population models predictive of pharmacokinetics across
paediatric populations? Br J Clin Pharmacol 72: 454–464. doi:10.1111/j.1365-
2125.2011.03992.x.
7. Kaguelidou F, Amiel P, Blachier A, Iliescu C, Roze´ J-C, et al. (2013)
Recruitment in pediatric clinical research was influenced by study characteristics
and pediatricians’ perceptions: a multicenter survey. J Clin Epidemiol 66: 1151–
1157. doi:10.1016/j.jclinepi.2013.04.015.
8. Whitehead J, Stratton I (1983) Group sequential clinical trials with triangular
continuation regions. Biometrics 39: 227–236.
9. Moran C, Smith PB, Cohen-Wolkowiez M, Benjamin DK Jr (2009) Clinical trial
design in neonatal pharmacology: effect of center differences, with lessons from
the Pediatric Oncology Cooperative Research experience. Clin Pharmacol Ther
86: 589–591. doi:10.1038/clpt.2009.175.
10. Jairath N, Weinstein J (1994) The Delphi methodology (Part one): A useful
administrative approach. Can J Nurs Adm 7: 29–42.
11. Powell C (2003) The Delphi technique: myths and realities. J Adv Nurs 41: 376–
382.
12. Green B, Jones M, Hughes D, Williams A (1999) Applying the Delphi technique
in a study of GPs’ information requirements. Health Soc Care Community 7:
198–205.
13. Keeney S, Hasson F, McKenna H (2006) Consulting the oracle: ten lessons from
using the Delphi technique in nursing research. J Adv Nurs 53: 205–212.
doi:10.1111/j.1365-2648.2006.03716.x.
14. Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C (2011) Using and
reporting the Delphi method for selecting healthcare quality indicators: a
systematic review. PloS One 6: e20476. doi:10.1371/journal.pone.0020476.
15. Ruperto N, Eichler I, Herold R, Vassal G, Giaquinto C, et al. (2012) A
European Network of Paediatric Research at the European Medicines Agency
(Enpr-EMA). Arch Dis Child 97: 185–188. doi:10.1136/archdischild-2011-
300286.
16. Horbar JD, Soll RF, Edwards WH (2010) The Vermont Oxford Network: a
community of practice. Clin Perinatol 37: 29–47. doi:10.1016/
j.clp.2010.01.003.
17. Lannon CM, Peterson LE (2013) Pediatric collaborative improvement networks:
background and overview. Pediatrics 131 Suppl 4: S189–195. doi:10.1542/
peds.2012-3786E.
18. Billett AL, Colletti RB, Mandel KE, Miller M, Muething SE, et al. (2013)
Exemplar pediatric collaborative improvement networks: achieving results.
Pediatrics 131 Suppl 4: S196–203. doi:10.1542/peds.2012-3786F.
19. Horbar JD (1999) The Vermont Oxford Network: evidence-based quality
improvement for neonatology. Pediatrics 103: 350–359.
20. Hasson F, Keeney S, McKenna H (2000) Research guidelines for the Delphi
survey technique. J Adv Nurs 32: 1008–1015.
21. Campbell MK, Snowdon C, Francis D, Elbourne D, McDonald AM, et al.
(2007) Recruitment to randomised trials: strategies for trial enrollment and
participation study. The STEPS study. Health Technol Assess Winch Engl 11:
iii, ix–105.
22. Shilling V, Williamson PR, Hickey H, Sowden E, Smyth RL, et al. (2011)
Processes in recruitment to randomised controlled trials of medicines for
children (RECRUIT): a qualitative study. Health Technol Assess Winch Engl
15: 1–116. doi:10.3310/hta15150.
23. Doyle LW (2006) Evaluation of neonatal intensive care for extremely-low-birth-
weight infants. Semin Fetal Neonatal Med 11: 139–145. doi:10.1016/
j.siny.2005.11.009.
24. Lake ET, Staiger D, Horbar J, Cheung R, Kenny MJ, et al. (2012) Association
between hospital recognition for nursing excellence and outcomes of very low-
birth-weight infants. JAMA J Am Med Assoc 307: 1709–1716. doi:10.1001/
jama.2012.504.
25. Franck LS (2005) Research with newborn participants: doing the right research
and doing it right. J Perinat Neonatal Nurs 19: 177–186.
26. Bush A (2006) Clinical trials research in pediatrics: strategies for effective
collaboration between investigator sites and the pharmaceutical industry.
Paediatr Drugs 8: 271–277.
27. Richey RH, Shah UU, Peak M, Craig JV, Ford JL, et al. (2013) Manipulation of
drugs to achieve the required dose is intrinsic to paediatric practice but is not
supported by guidelines or evidence. BMC Pediatr 13: 81. doi:10.1186/1471-
2431-13-81.
28. Nahata MC, Allen LV Jr (2008) Extemporaneous drug formulations. Clin Ther
30: 2112–2119. doi:10.1016/j.clinthera.2008.11.020.
29. Griffin T (2006) Family-centered care in the NICU. J Perinat Neonatal Nurs 20:
98–102.
30. Ward FR (2010) Parents’ views of involvement in concurrent research with their
neonates. J Empir Res Hum Res Ethics JERHRE 5: 47–55. doi:10.1525/
jer.2010.5.2.47.
31. McKechnie L, Gill AB (2006) Consent for neonatal research. Arch Dis Child
Fetal Neonatal Ed 91: F374–376. doi:10.1136/adc.2005.075036.
32. Me´noni V, Lucas N, Leforestier J-F, Doz F, Chatellier G, et al. (2011)
Readability of the Written Study Information in Pediatric Research in France.
PLoS ONE 6: e18484. doi:10.1371/journal.pone.0018484.
33. Laventhal N, Tarini BA, Lantos J (2012) Ethical issues in neonatal and pediatric
clinical trials. Pediatr Clin North Am 59: 1205–1220. doi:10.1016/
j.pcl.2012.07.007.
Delphi Process to Perform Drugs Trials in NICUs
PLOS ONE | www.plosone.org 15 September 2014 | Volume 9 | Issue 9 | e104976
